Use of OCT Angiography in Choroidal Melanocytic Tumors.
Conclusion: OCTA is a promising new technology that can be used to study in vivo the differential characteristics of microcirculations between posterior segment melanocytic lesions. Today, larger studies are needed to corroborate these findings and to correlate it with malignancy. PMID: 29201456 [PubMed]
Eyelids metastases from uveal melanoma: clinical and histopathologic features of two cases and literature review, Published online: 18 December 2018; doi:10.1038/s41433-018-0317-7Eyelids metastases from uveal melanoma: clinical and histopathologic features of two cases and literature review
To describe the superiority of ocular ultrasound in the diagnostic management of extrascleral extension in choroidal melanoma.
Conditions: Cancer; Melanoma (Skin); Melanoma, Uveal; Melanoma, Ocular; Bladder Cancer; Mismatch Repair Deficiency; Microsatellite Instability; Non-melanoma Skin Cancer Interventions: Biological: RP1; Biological: nivolumab Sponsor: Replimune Inc. Recruiting
CONCLUSION: For the primary treatment of iridal melanoma a surgical, eyeball-sparing approach and also when appropriate, radiotherapy can be recommended. In the future, eligible high-risk patients could profit from a tumor vaccination. To date, there is no effective systemic treatment for metastatic iridal melanoma. PMID: 30515574 [PubMed - as supplied by publisher]
This secondary analysis of medical records assesses the specific risks of plaque-irradiated small choroidal melanoma on visual acuity and metastasis for small choroidal melanoma 3 mm thick or less.
Over the last several decades, ocular oncologists have set a goal to identify and treat smaller uveal melanomas. Another way to rephrase this goal would be to state that we want to identify melanocytic lesions that are likely to spread at some future time and ablate them before they do so. Ocular oncologists are very accurate in diagnosing medium and large uveal melanomas. Differentiation of small melanomas from high-risk choroidal nevi has been more challenging. Approximately 8% of people in the United States have a choroidal nevus. The malignant transformation rate is estimated at about 1 in 9000 per year. This translate...
To the Editor We read with great interest the article by Dalvin et al concerning the association between myotonic dystrophy (DM1) and uveal melanoma. Recent evidence has shown that uveal melanoma is associated with mutations in genes responsible for the eye colors, with a higher disease prevalence in individuals with lighter-colored eyes. We agree with the authors on the importance of an accurate ophthalmic examination in patients with DM1, because they may present with many ophthalmic diseases across the life span. However, we believe it is important to put their findings into context with other large studies.
PMID: 30503012 [PubMed - in process]
CONCLUSION: Findings related to choroidal melanoma regression after 103Pd plaque brachytherapy included decreased intrinsic tumor vascularity, decreased tumor-related subretinal fluid, increased pigmentation, specific changes in orange pigment lipofuscin and resolution of drusenoid retinal pigment epithelial detachments, as well as decreased tumor thickness with an increase in internal reflectivity on ultrasound. PMID: 29788760 [PubMed - as supplied by publisher]
Authors: Mor JM, Koch KR, Heindl LM Abstract The most common iris lesions are iris nevi, iris melanomas and iris pigment epithelium cysts. However, there is an abundance of rare differential diagnoses that have to be considered, including other melanocytic and non-melanocytic lesions. Diagnostic tools include the slit lamp examination, gonioscopy, tonometry, transillumination, ultrasound biomicroscopy (UBM), optical coherence tomography, fluorescein angiography and standardized photography-assisted documentation. The timely identification of malignant lesions (i.e. iris melanoma) is paramount. To assess malignancy ...